Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relay Therapeutics, Inc. - Common Stock (NQ: RLAY )

3.410 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Relay Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023
Via Benzinga
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2023 – USA News Group – Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs... 
Via FinancialNewsMedia
Relay Therapeutics's Return On Capital Employed Overview
Via Benzinga
Relay Therapeutics Earnings Preview
Via Benzinga
5 Analysts Have This to Say About Relay Therapeutics
Relay Therapeutics (NASDAQ:RLAY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Expert Ratings for Relay Therapeutics
Within the last quarter, Relay Therapeutics (NASDAQ:RLAY) has observed the following analyst ratings: 
Via Benzinga
Evogene Offers An Excellent Risk/Reward Ratio
We think the company’s main CPB computational engine has the potential to be an extraordinary value creation engine. Investors only need one of the company's subsidiaries to succeed, to de-risk their... 
Via Talk Markets
Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR
Relay Therapeutics to host conference call following AACR presentation 
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
4 Analysts Have This to Say About Relay Therapeutics
Within the last quarter, Relay Therapeutics (NASDAQ:RLAY) has observed the following analyst ratings: 
Via Benzinga
Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
Via Benzinga
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
Relay Therapeutics to Participate in Guggenheim Healthcare Talks | Oncology Day
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion. 
Via Benzinga
Relay Therapeutics's Earnings Outlook
Relay Therapeutics (NASDAQ:RLAY) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Relay... 
Via Benzinga
Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2022
Upgrades 
Via Benzinga
7 Unknown Biotech Stocks That Could Rocket in 2023
Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline. 
Via InvestorPlace
Wells Fargo Slashes Price Target On This Stock By Over 71%, Also Check Out Other Major PT Changes Here
Wells Fargo cut the price target on Cabaletta Bio, Inc. (NASDAQ: CABA) from $14 to $4. Wells Fargo analyst Derek Archila maintained the stock with an Overweight rating. Cabaletta Bio shares gained 0.9%... 
Via Benzinga
Tesla, Meta, NVIDIA And Other Big Losers From Tuesday
U.S. stocks closed sharply lower with the Nasdaq Composite dipping more than 5% on Tuesday. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX... 
Via Benzinga
Why Relay Therapeutics Shares Are Getting Hammered
Relay Therapeutics Inc (NASDAQ: RLAY) shares are trading lower by 11.33% to $25.54 Tuesday morning after the company priced a roughly 11.32 million share public offering of common stock at $26.50 per... 
Via Benzinga
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.